Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become tomorrow’s laggard without continuous development ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply ...

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11. Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue. Eli Lilly reported net income of $4.41 billion, or $4. ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings ...